Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese

Breadcrumb

  1. Home
  2. Microbiota 16 - October 2022
  3. Immune regulation by fungal strain diversity in inflammatory bowel disease
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Microbiota 16 - October 2022
  3. Immune regulation by fungal strain diversity in inflammatory bowel disease
Gastroenterology

Immune regulation by fungal strain diversity in inflammatory bowel disease

Gastroenterology
IBD

COMMENTED ARTICLE - ADULTS’ SECTION

By Pr. Harry Sokol
Gastroenterology and Nutrition Department, Saint-Antoine Hospital, Paris, France

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographics
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

Microbiota 16 articles commentés

About this article

Created 04 October 2022
Updated 06 October 2022

Comments on the article by Li XV et al. Nature 2022 [1]

The fungal microbiota (mycobiota) is an integral part of the complex microbial community colonising the mammalian gastro-intestinal tract and has an important role in immune regulation. Although changes in the mycobiota have been linked to several diseases, including inflammatory bowel disease (IBD), it is currently unknown whether fungal species identified by sequencing represent living organisms and whether specific fungi have effects on the development of IBD. The authors developed a translational platform for the function al analysis of the mycobiome. By combining high-resolution mycobiota sequencing, fungal culturomics and genomics, a CRISPR-Cas9-based fungal strain editing system, in vitro functional immunoreactivity assays and in vivo models, this platform enables the examination of host-fungal crosstalk in the human gut. We discovered a rich genetic diversity of opportunistic Candida albicans strains that dominate the colonic mucosa of patients with IBD. Among these isolates, strains with high immune-cell-damaging capacity (HD strains) reflect the disease features of patients with ulcerative colitis and aggravate intestinal in flammation in vivo through IL-1β-dependent mechanisms. The inflammatory and antifungal responses of interleukin-17A-producing T helper cells (Th17 cells) induced by the HD strains in the gut were dependent on candidalysin, the peptide toxin secreted by C. albicans during the transition from a benign commensal to a pathobiont state. These findings reveal the strain-specific nature of host-fungal interactions in the human gut and highlight new diagnostic and therapeutic targets for IBD.

WHAT DO WE ALREADY KNOW ABOUT THIS SUBJECT?

Studies based on deep sequencing of the gut mycobiota in several cohorts of patients supply coherent evidence that «fungal dysbiosis» is a characteristic of chronic inflammatory bowel disease (IBD) [2], the most widespread forms of which are Crohn’s disease (CD) and ulcerative colitis (UC), which affect millions of individuals worldwide. Anti-Saccharomyces cerevisiae antibodies (ASCA), directed against the mannans presented by the cell wall of fungi, define sub-types of IBD, because their presence in the serum is associated with CD but not with UC, which establishes an additional link between fungi and IBD. Candida is the most widespread fungal genus, and its presence is systematically increased in several cohorts of patients with IBD analysed by sequencing of the faecal microbiota [2].

In particular, C. albicans in the gut induces a set of antifungal antibodies and acts as an immunogen for ASCA. Candida species associated with the gut mucosa are detected by the macrophages present in the gut and have been shown experimentally to have the potential to induce protective immunity or to trigger inflammation, depending on the context [3]. Despite this evidence, it is currently unknown whether the fungi detected by sequencing technologies in the human gut have an essential role in the orientation of mucosal immunity or in the evolution of inflammatory disease in each individual patient. A lack of correlation has been repeatedly observed between changes in the composition of the mycobiota and the seriousness of the disease in IBD patient cohorts, despite a constant increase in Candida species. The authors have therefore emitted the hypothesis that the functional diversity of Candida strains determines the host-fungal relationship in human gut mucosa with an effect on intestinal inflammation.

KEY POINTS

  • The mycobiota is changed in patients with IBD and Candida albicans has pro-inflammatory effects
  • The pro-inflammatory effects of C. albicans vary from one strain to another and are associated with the capacity to induce cell lesions in the macrophages and to filament
  • The pro-inflammatory effects of these strains of C. albicans are mediated by the production of candidalysin and the induction of IL-1β production
  • C. albicans, candidalysin and IL-1β are potential therapeutic targets in UC

WHAT ARE THE MAIN INSIGHTS FROM THIS STUDY?

In agreement with numerous other studies, the authors first observed that the mycobiota of patients with UC were rich in Candida albicans and, in contrast, poor in Saccharomyces. In the situation of impaired immune response induced by corticosteroid therapy, C. albicans exacerbates the severity of colitis in mice. The authors then isolated several strains of C. albicans from the mycobiota of healthy subjects and from patients with UC and observed a wide heterogeneity in terms of pro-inflammatory capacity. In particular, the capacity of causing cell damage to the macrophages, which are a key defence against fungi, varies from one strain to another. The strains able to inflict cell damage to the macrophages have a greater tendency to filament and have pro-inflammatory effects in vivo by inducing a Th17 response (Figure 1). The authors then showed that a large part of the pro-inflammatory effects were mediated by the secretion of a toxin, candidalysin, and the induction of IL-1β production. Subsequent analyses revealed a strong correlation between the pro-inflammatory capacity of strains isolated from patients with UC and the inflammatory activity of the disease. On the other hand, there was no correlation between the magnitude of intestinal inflammation and the overall abundance of Candida albicans in the patients. These results explain why the composition of the mycobiota is poorly correlated to the characteristics of human pathologies and suggest that the functional capacities (pro-inflammatory in this case) may provide a better explanation of the role of the mycobiota in these pathologies.

Image
Microbiota 16 articles commentés Fig1

WHAT ARE THE CONSEQUENCES IN PRACTICE?

This study shows that, in addition to analyses of the composition of the mycobiota, in particular by sequencing, a functional analysis is necessary to understand its contribution to the disease and in particular in IBD. If pro-inflammatory strains of C. albicans, candidalysin and IL-1β are confirmed to have a role in UC, we can imagine a therapeutic option which targets one of these elements, especially as several molecules which antagonise the IL-1β pathway are already available.

Conclusion

This study suggests that candidalysin is a key factor in the pro-inflammatory effect of C. albicans in the gut and that some highly pro-inflammatory strains act via IL-1β-dependent mechanisms. Patients who are carriers of highly pro-inflammatory strains may represent a target population for a treatment antagonising IL-1 and/or C. albicans.

Sources

1. Li XV, Leonardi I, Putzel GG, et al. Immune regulation by fungal strain diversity in inflammatory bowel disease. Nature 2022 ; 603 : 672-8.
2. Sokol H, Leducq V, Aschard H, et al. Fungal microbiota dysbiosis in IBD. Gut 2017 ; 66 : 1039-48.
3. Doron I, Leonardi I, Li XV, et al. Human gut mycobiota tune immunity via CARD9-dependent induction of anti-fungal IgG antibodies. Cell 2021 ; 184 : 1017-1031.e14.

Tags
Gut microbiota IBD Gastroenterology Gastrointestinal tract

en_view en_sources

    Focus
    Microbiota 16 - October 2022
    • Overview
      • Gut microbiota and stress-related disorders
      • The interaction between the oral microbiota and SARS-COV-2 infection
    • Commented article
      • Immune regulation by fungal strain diversity in inflammatory bowel disease
      • Bacteroidota and Lachnospiraceae integration into the gut microbiome at key time points in early life are linked to infant neurodevelopment
    • Congress review
      • Highlights from the 54th Espghan
    • Press review
      • Gut Microbiota # 16
      • Vaginal Microbiota # 16
    • Expert opinion
      • Association between IBD and greater amounts of microplastics in stool
    Created 04 October 2022
    Updated 06 October 2022

    About this article

    To know more about this topic.

    Main topic

    Gastroenterology

    Medical practice

    IBD

    Content type

    Commented article
    The interaction between the oral microbiota and SARS-COV-2 infection
    Bacteroidota and Lachnospiraceae integration into the gut microbiome at key time points in early life are linked to infant neurodevelopment
    Focus

    Microbiota 16 - October 2022

    Overview

    Gut microbiota and stress-related disorders The interaction between the oral microbiota and SARS-COV-2 infection

    Commented article

    Immune regulation by fungal strain diversity in inflammatory bowel disease Bacteroidota and Lachnospiraceae integration into the gut microbiome at key time points in early life are linked to infant neurodevelopment

    Congress review

    Highlights from the 54th Espghan

    Press review

    Gut Microbiota # 16 Vaginal Microbiota # 16

    Expert opinion

    Association between IBD and greater amounts of microplastics in stool
    Gastroenterology
    L’axe intestin-cerveau dans le stress lié à la discrimination
    20.03.2023

    The gut-brain axis and discrimination-related stress

    Read the article
    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article
    09.03.2023

    Each subtype of Irritable Bowel Syndrome (IBS) has its own dysbiosis

    Read the article
    Parkinson : le microbiote intestinal, chef d’orchestre des mécanismes pathogéniques ?
    27.02.2023

    Does the gut microbiota orchestrate pathogenic mechanisms in Parkinson’s disease?

    Read the article

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irritable Bo...

    Find out more

    Human milk nutrient fortifiers alter the developing gastrointestinal microbiota of very-low-birth-weight infants

    Commented article - Children's section By Pr. Emmanuel M...

    Find out more

    Impact of beer and non alcoholic consumption on the gut microbiota

    By Pr. Bernd SchnablDivision of Gastroenterology, San Diego Digestive Diseases Research Center (SDDRC), UC ...

    Find out more
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian
    • Portuguese

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    L’axe intestin-cerveau dans le stress lié à la discrimination
    20.03.2023

    The gut-brain axis and discrimination-related stress

    Read the article
    20.03.2023

    The role of Bifidobacteria in irritable bowel syndrome (IBS)

    Read the article
    14.03.2023

    Positive impact of running on gut microbiota and adolescent depression

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographics
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo